在铁变态反应和癌症中靶向 GPX4：化学策略与挑战。

IF 13.9 1区医学 Q1 PHARMACOLOGY & PHARMACY

Trends in pharmacological sciences Pub Date : 2024-08-01 Epub Date: 2024-06-11 DOI:10.1016/j.tips.2024.05.006

Jiao Liu, Daolin Tang, Rui Kang

引用次数: 0

摘要

硒蛋白谷胱甘肽过氧化物酶 4（GPX4）是氧化应激诱导的铁变态反应的关键抑制因子，使其成为具有吸引力的疾病治疗靶点。在此，我们将讨论通过共价抑制剂、蛋白水解靶向嵌合体（PROTAC）降解剂和细胞类型特异性降解剂靶向 GPX4 治疗癌症的最新策略和挑战。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Targeting GPX4 in ferroptosis and cancer: chemical strategies and challenges.

Selenoprotein glutathione peroxidase 4 (GPX4) serves as a crucial suppressor of oxidative stress-induced ferroptosis, making it an attractive target for disease therapy. Here, we discuss recent strategies and challenges associated with targeting GPX4 through covalent inhibitors, proteolysis targeting chimera (PROTAC) degraders, and cell-type-specific degraders in the context of cancer.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Trends in pharmacological sciences 医学-药学

CiteScore

23.90

自引率

0.70%

发文量

132

审稿时长

6-12 weeks

期刊介绍： Trends in Pharmacological Sciences (TIPS) is a monthly peer-reviewed reviews journal that focuses on a wide range of topics in pharmacology, pharmacy, pharmaceutics, and toxicology. Launched in 1979, TIPS publishes concise articles discussing the latest advancements in pharmacology and therapeutics research. The journal encourages submissions that align with its core themes while also being open to articles on the biopharma regulatory landscape, science policy and regulation, and bioethics. Each issue of TIPS provides a platform for experts to share their insights and perspectives on the most exciting developments in the field. Through rigorous peer review, the journal ensures the quality and reliability of published articles. Authors are invited to contribute articles that contribute to the understanding of pharmacology and its applications in various domains. Whether it's exploring innovative drug therapies or discussing the ethical considerations of pharmaceutical research, TIPS provides a valuable resource for researchers, practitioners, and policymakers in the pharmacological sciences.